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CARCINOMA OF THE KIDNEY 
Tumors of the upper urinary tract constitute 1 % 
to 2% of all cancers, and each year 11 ,000 new cases 
are diagnosed in the United States. Approximately 
half of these patients have metastatic disease at the 
time of diagnosis. H ypernephroma, or renal cell car-
cinoma, was first described in 1863 by Grawitz. These 
tumors arise from tubular epithelial cells and are 
correctly termed renal cell carcinoma or renal cell 
adenocarcinoma. There is evidence that further iden-
tifies the cell of origin as being from the proximal 
convoluted tubular epithelium. There does not ap-
pear to be a specific racial or ethnic incidence al-
though it occurs three times more often in men than 
in women. Few epidemiological studies of this disease 
have been undertaken, although there is some associ-
ation between the use of tobacco and an increased 
incidence of renal cell carcinoma. The classical triad 
of hematuria, pain, and a palpable mass are late 
findings with a poor prognosis which occurs in 10% 
of the patients and usually represents metastatic dis-
ease. Forty percent of the patients may have hema-
turia or other urinary complaints. Local effects of the 
tumors are hematuria, pain, and a flank mass, but the 
presenting symptoms may include a varicocele in the 
male which is produced by direct pressure of the 
tumor on the spermatic vein or because of stasis 
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caused by an obstructing tumor thrombus in the vena 
cava. Systemic toxic effects such as hyperpyrexia may 
be of an intermittent or variable nature. Anemia or 
abnormal liver chemistries may also be present. 
Erythrocytosis, hypertension, and hypercalcemia 
may also be manifest. 
Once a renal mass is found, a number of proce-
dures can be followed in order to evaluate the patient 
before surgery. These include the use of intravenous 
excretory urography, retrograde pyelography, neph-
rotomography, renal angiography, and venacavo-
graphy, along with sonographic examination of renal 
masses and the evaluation of renal masses by the use 
of computerized axial tomography. 
The staging classification developed by Robeson 
is probably the most widely accepted: Stage I-tu-
mor confined within the kidney; stage 2-perirenal 
fat involvement confined within Gerota fascia; stage 
3-a. gross renal vein or inferior vena cava in-
volvement, b. lymphatic involvement, and c. vascular 
and lymphatic involvement; stage 4-a. adjacent or-
gans other than the adrenal involved, and b. distant 
metastases. Renal vein involvement without peri-
nephric involvement or lymphatic spread does not 
seem to alter the prognosis at 5-10 years where lym-
phatic involvement is an ominous sign. 
Treatment 
Surgical removal of the tumor for cure is the 
basic management of the patient with hyper-
nephroma. The single, most significant advance in 
technique and its influence on survival were pointed 
out in 1968 by Robeson, who used the combination 
of early ligation of the renal artery and vein, complete 
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removal of the perinephric envelope, and surgical 
extirpation of the lymphatic field. Caution in han-
dling of the renal vein is important, especially if there 
is tumor involvement of the veins, as portions of 
renal vein tumor may break off and cause acute pul-
monary embolization. 
Preoperative Radiation 
Several investigators have advocated the use of 
preoperative radiation in the management of renal 
cancer, but random clinical trials to date have not 
shown that this has improved long-term survival. In 
certain patients, however, a preoperative course of 
radiotherapy of 3,000-4,000 rads to the kidney in four 
weeks has markedly decreased the vascularity of the 
tumor. There is some evidence that postoperative 
radiotherapy may have a beneficial effect on survival 
statistics, especially if there has been extracapsular 
invasion and tumor has been left behind. 
Chemotherapy 
The use of chemotherapy in the management of 
metastatic renal carcinoma has proven particularly 
disappointing. Good results have been quoted by 
some investigators with the use of medroxyprogeste-
rone (Provera) 100 mg t.i.d . and a number of other 
chemotherapeutic agents singly or in combination. 
Special Management Problems 
Involvement of the renal vein and vena cava are 
of interest because of the possible use of extra-
corporal circulation in order to approach the patient 
with tumor thrombus in the renal vein, the vena cava, 
and the atrium of the heart. 
Carcinoma arising in a solitary kidney provides 
a real therapeutic dilemma. Procedures such as par-
tial nephrectomy in situ, bench surgery with the re-
moval of the kidney, perfusing the kidney for preser-
vation, surgical excision of the tumor with repair of 
the kidney and autotransplantation back into the 
patient, and total extirpation with homotransplan-
tation at a later date have all been used. 
Approximately 12% of upper urinary tract ma-
lignancies are from renal pelvic tumors. These are 
often transitional cell carcinomas, but a few are of the 
squamous cell variety. The diagnosis is usually based 
on the appearance of a filling defect on intravenous 
urography or retrograde pyelography. A differential 
diagnosis from a nonopaque stone or blood clot may 
be difficult. As these tumors tend to be multiple, the 
therapy for them is total removal of the kidney and 
renal pelvis with removal of the entire ureter and a 
cuff of bladder. For those people who have under-
gone only partial removal of the ureter, recurrence in 
the stump of ureter has been high. 
BLADDER CANCER 
Carcinoma of the urinary bladder accounts for 
4% to 5% of all new cancers. Approximately 30,000 
new cases of bladder cancer are found in the United 
States each year resulting in over 9,500 deaths. The 
incidence is three times more prominent in men than 
in women and four times more common in whites 
than in non-whites. Age distribution reveals a peak in 
patients 75-84 years of age, and 80% of these tumors 
occur after age 50. 
The known and suspected causes of bladder can-
cer are grouped into four categories: 1) Industrial 
chemicals; 2) metabolites of foodstuffs; 3) tobacco 
tar; and 4) chronic mechanical irritation and infec-
tion. 
All but 3% to 4% of bladder tumors originate in 
the transitional cell epithelium . Transitional cell car-
cinoma of the bladder occurs in approximately 90% 
of the patients, with squamous cell carcinoma ac-
counting for 6% to 7% and adenocarcinoma 1 % to 
2%. Transitional cell carcinomas may be very small 
and papillary in character but may be multiple, large 
and sessile tumors; the surface may be intact or ulcer-
ated, crusted, and bleeding. Squamous cell cancer, on 
the other hand, is usually flat, ulcerated, and some-
times necrotic; adenocarcinoma appears grossly as 
transitional or squamous and must be differentiated 
microscopically. 
Diagnosis 
Painless, gross hematuria is found in 75% to 85% 
of the patients presenting with carcinoma of the blad-
der. As the tumor enlarges, other symptoms such as 
frequency, urgency, dysuria, and decrease in caliber 
or force of the urinary stream may be present. These 
symptoms may be secondary to infection of the blad-
der or may be irritations caused by the tumor. As the 
tumor progresses, the suprapubic pain and a palpable 
mass may become prominent, these being associated 
with obstructive uropathy and uremia. 
The diagnosis is made at the time of cystoscopy 
when a tumor is seen and biopsies can be obtained. It 
is important that a rectal and bi-manual examination 
be done to assess the size of the mass. A palpable, 
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hard, indurated mass is usually a sign of an advanced 
tumor and a poor prognosis. 
Intravenous urography is an important step in 
the assessment of the patient with bladder cancer. 
The urogram will indicate the functional status of the 
kidneys and the possibilities of ureteral obstruction. 
By using triple-phase contrast studies of the bladder, 
one can ascertain fixation of the bladder wall and the 
possibility of invasion. If this is combined with pelvic 
arteriography in conjunction with perivesical and in-
travesical gas or with computerized axial tomogra-
phy, a better evaluation of the size of the tumor may 
be found. 
Grading and Staging 
All tumors can be graded histologically based on 
the degree of cellular anaplasia. Grade I or well-
differentiated tumor has a much better prognosis 
than a grade III or IV or poorly differentiated tumor. 
Staging in the United States has usually been by the 
A, B, C, D classification of Jewett and Strong, and 
Marshall. Recently the TNM (Tumor, Nodes, Metas-
tasis) classification of the International Union 
Against Cancer has been publicized in order to get 
physicians in the United States to switch to that 
classification of all tumors. In general, however, a 
stage O tumor is one that is localized only to the 
mucosa; stage A is limited to the submucosa, and 
stage 8 1 indicates that the tumor has invaded the 
bladder muscle but is less than half-way through the 
bladder wall. Stage 8 2 tumors extend through the 
bladder muscle but do not invade the perivesical fat, 
and stage C indicates perivesical fat involvement or 
involvement of the capsule of another organ. Stage 
D, tumors are those that have spread to the regional 
pelvic lymph nodes or have invaded the pelvic wall or 
rectus muscle or both. Stage 0 2 tumors exist when 
the tumor has spread beyond these limitations and is 
outside the pelvis and the immediate bladder area. 
Metastases occur most often to the regional lymph 
nodes, lungs, liver, and bone. 
Treatment 
The treatment of the patient with a superficial 
tumor is usually by means of endoscopic surgery with 
transurethral resection. Careful follow-up examina-
tion with repeat cystoscopies every three months for 
one year, and every six months for five years, and 
every year thereafter are necessary in order that any 
residual or recurrent tumors may be promptly found 
and the appropriate treatment instituted. For the pa-
tient with multiple recurring tumors, the use of intra-
vesical therapy (ThioTepa), partial or total removal 
of the bladder, or radiation are possible therapeutic 
choices. For the patient with invasive transitional cell 
carcinoma, endoscopic procedures are not adequate. 
One cannot endoscopically tell the degree and extent 
of the tumor, therefore, an open surgical procedure 
with removal of the entire tumor or radiation therapy 
is indicated. It would appear as of this writing, that 
the best results are obtained from preoperative radia-
tion followed by open surgical extirpation of the tu-
mor, usually a radical cystectomy with urinary diver-
sion. There is some discussion about whether 2,000 
rads in one week , 4,000 rads in 4 weeks, or 4,500 rads 
in 6 weeks followed by either immediate or delayed 
cystectomy is best. 
Chemotherapy 
Long-term survival is rare once the tumor has 
spread beyond the confines of the bladder. One 
means of destroying metastases, however, may be 
through the use of combinations of chemotherapeutic 
agents. Drugs used in the management of patients 
with transitional cell carcinoma of the bladder have 
been 5-fluorourocil, bleyomycin, adriamycin, cyclo-
phosphamide (Cytoxan) and the cis-platinum com-
pounds. 
